These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33019803)

  • 21. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
    Yang J; Chen J; Ji Y; Tang Q; Zhang R; Liu L; Shen Y; Xun J; Song W; Tang Y; Wang Z; Qi T; Lu H
    Int J Infect Dis; 2019 Jun; 83():64-71. PubMed ID: 30951879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
    Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
    J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy.
    Guo F; Song X; Li Y; Guan W; Pan W; Yu W; Li T; Hsieh E
    Osteoporos Int; 2021 Feb; 32(2):321-332. PubMed ID: 32803316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
    Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G
    AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.
    LaFleur J; Bress AP; Esker S; Knippenberg K; Crook J; Nyman H; Bedimo R; Tebas P; Rosenblatt L
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):325-330. PubMed ID: 29210830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
    Hawkins T; Veikley W; St Claire RL; Guyer B; Clark N; Kearney BP
    J Acquir Immune Defic Syndr; 2005 Aug; 39(4):406-11. PubMed ID: 16010161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.
    Wang H; Lu X; Yang X; Xu N
    Medicine (Baltimore); 2016 Oct; 95(41):e5146. PubMed ID: 27741146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
    Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
    Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
    Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
    Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray study.
    Shahmanesh M; Phillips K; Boothby M; Tomlinson JW
    PLoS One; 2015; 10(1):e0117164. PubMed ID: 25617630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
    Balestre E; Dupon M; Capdepont S; Thiébaut R; Boucher S; Fleury H; Dabis F; Masquelier B;
    J Clin Virol; 2006 Jun; 36(2):95-9. PubMed ID: 16556509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
    Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.
    Hemkens LG; Ewald H; Santini-Oliveira M; Bühler JE; Vuichard D; Schandelmaier S; Stöckle M; Briel M; Bucher HC
    HIV Clin Trials; 2015 Oct; 16(5):178-89. PubMed ID: 26395328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
    Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
    HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.
    Flandre P; Pugliese P; Allavena C; Katlama C; Cotte L; Cheret A; Cabié A; Rey D; Chirouze C; Bani-Sadr F; Cuzin L;
    HIV Med; 2016 May; 17(5):380-4. PubMed ID: 27093565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.